Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for 10x Genomics, Inc. (NASDAQ: TXG), a life science technology company specializing in single cell and spatial biology. Through these filings, investors and researchers can review the company’s regulatory disclosures, including annual and quarterly reports and current reports on material events.
10x Genomics’ Class A common stock is registered on The Nasdaq Stock Market LLC under the symbol TXG, as noted in its Form 8-K filings. The company uses SEC filings, along with its website, press releases, public conference calls, webcasts and social media accounts, as channels for disclosing information and for complying with Regulation FD. Form 8-K filings have addressed topics such as quarterly financial results and changes in certain executive roles.
Key SEC documents for TXG include annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed information about revenue by product type and geography, gross margin, operating expenses, cash and marketable securities, and risk factors. Current reports on Form 8-K provide timely updates on specific events, such as earnings releases or leadership changes. Together, these filings give a structured view of how 10x Genomics’ single cell and spatial biology business is performing and evolving.
On Stock Titan, users can view TXG filings as they are made available from EDGAR and use AI-powered summaries to interpret complex sections, such as revenue breakdowns, operating results and risk disclosures. Filings related to topics like license and royalty revenue, services, and geographic revenue distribution can be examined to understand the company’s financial profile. This page also offers convenient access to insider and governance-related filings, helping users track corporate developments over time.
FMR LLC and Abigail P. Johnson report beneficial ownership of 12,696,254.11 shares of 10x Genomics, Inc. Class A common stock, representing 10.8% of that class as of December 31, 2025. FMR has sole voting power over 12,658,759 shares and sole dispositive power over 12,696,254.11 shares, with no shared voting or dispositive power.
The reported amount includes 892,772 shares of Class B common stock held by investment companies advised by FMR subsidiaries, which are convertible into Class A shares on a 1:1 basis and represent 8.8579% of the outstanding Class B stock. The filing states that, assuming conversion of all outstanding Class B into Class A, the reported holding would represent 10.0324% of the Class A common stock. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of 10x Genomics.
10x Genomics, Inc. reported that Chief Executive Officer and director Serge Saxonov exercised stock options on January 5, 2026 to acquire 50,000 shares of Class A common stock at $1.20 per share. These shares now form part of his directly held stake of 1,071,556 Class A shares following the transaction.
The filing shows two option exercises, covering 17,463 and 32,537 underlying shares, from fully vested options expiring on October 18, 2027, leaving 173,600 stock options outstanding. In addition to his direct holdings, Saxonov is reported as trustee for three trusts that hold 27, 213,250 and 58,000 Class A shares, respectively.
10x Genomics, Inc. (TXG) reported an insider stock transaction by its Chief Financial Officer. On 11/24/2025, the CFO disposed of 11,888 shares of Class A common stock in a sale transaction at a price of $18.9983 per share. After this transaction, the officer beneficially owns 297,385 shares of Class A common stock in direct ownership form.
The company notes that the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, meaning the transaction was connected to equity compensation rather than an open-market liquidation of a larger personal position.
10x Genomics, Inc. reported an insider stock transaction by a senior executive. On 11/24/2025, a reporting person who serves as both a director and as President and Chief Scientific Officer sold 8,283 shares of Class A common stock of 10x Genomics, Inc. (TXG) at a price of $18.9983 per share. According to the explanation provided, the shares were sold to cover tax withholding obligations that arose when restricted stock units vested, meaning the transaction was tied to equity compensation rather than a discretionary open-market sale.
After this transaction, the reporting person beneficially owned 432,605 shares of Class A common stock in direct form. The Form 4 was filed for a single reporting person and does not report any derivative securities activity.
10x Genomics, Inc. (TXG) Chief Executive Officer and Director Serge Saxonov reported a sale of Class A common stock in a Form 4 filing. On 11/24/2025, he sold 13,261 shares at an average price of $18.9983 per share in a transaction coded "S," which the notes explain was to cover tax withholding obligations from vesting restricted stock units.
After this transaction, Saxonov beneficially owns 1,021,556 Class A shares directly. He also reports indirect ownership of 27 shares through the Andromeda Trust, 213,250 shares through the Y/S Descendants' Trust, and 58,000 shares through the Y/S Pot Trust, where he serves as trustee.
10x Genomics (TXG) announced a planned legal leadership transition. Eric S. Whitaker will retire as Chief Legal Officer effective January 1, 2026, after more than eight years with the company. He will remain an employee with reduced compensation and serve as Strategic Counsel, continuing to advise on ongoing legal matters.
Dr. Randy Wu, currently Vice President of Intellectual Property and Litigation, has been appointed General Counsel and Secretary effective January 1, 2026. Wu joined the company in August 2016 following his tenure at Orrick, Herrington & Sutcliffe LLP, and holds a Ph.D. in Biophysics (UCSF) and a J.D. (Stanford). CEO Serge Saxonov highlighted Whitaker’s leadership through key milestones, and emphasized continuity with Wu’s internal promotion.
10x Genomics (TXG) reported Q3 2025 results with revenue of $149.0 million and a net loss of $27.5 million. Gross margin was 67%. Products and services revenue fell 2% year over year as instruments declined 37% to $12.0 million, while consumables rose 1% to $127.9 million and services grew 29% to $8.1 million.
Year-to-date, revenue reached $476.8 million$45.8 million of license and royalty revenue tied to settlements with Vizgen and Bruker, alongside a $49.9 million gain on settlement. Cash, cash equivalents, and marketable securities totaled $482.1 million as of September 30, 2025.
The company closed the Scale Biosciences asset acquisition with $9.2 million cash and $13.5 million in stock (1,099,992 shares), recorded $22.4 million of contingent consideration at fair value, and expects a $20.0 million payment in Q1 2026. A May 2025 restructuring recorded $6.0 million in charges. Management noted revenues are expected to moderately increase sequentially in Q4 2025 and gross margin may fluctuate with mix and non-recurring items.
10x Genomics (TXG) furnished an 8-K announcing quarterly results. The company reported that it issued a press release with financial results for the quarter ended September 30, 2025, and attached it as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not deemed filed under Section 18 of the Exchange Act.
10x Genomics’ Class A common stock trades on Nasdaq under the symbol TXG. The exhibit list includes the press release dated November 6, 2025 and the Inline XBRL cover page file.
Serge Saxonov, Chief Executive Officer and Director of 10x Genomics (TXG), filed a Form 4 reporting a transaction dated 09/12/2025 in which 900 shares of Class A common stock were disposed (code G). After the reported transaction, Mr. Saxonov directly beneficially owns 1,034,817 shares of Class A common stock. The filing also discloses substantial indirect and convertible holdings held in multiple trusts for which he serves as trustee, including convertible Class B shares that can convert into Class A shares and derivative holdings underlying 1,192,040 and 1,750,000 Class A shares as reported. Footnotes identify transfers on July 18, 2025 and several irrevocable trusts (each holding 250,000 shares) for which he is sole trustee, indicating estate or trust structuring of substantial ownership.
Serge Saxonov, who serves as Chief Executive Officer and a director of 10x Genomics, Inc. (TXG), reported a transaction on 08/22/2025 in which 9,348 shares of Class A common stock were sold at a price of $13.787 per share. The filing indicates the sale was made to cover tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the filing shows 945,892 shares held directly and additional indirect holdings reported as: 27, 89,825, 213,250, and 58,000 shares, each held via trusts for which the reporting person serves as trustee. The Form 4 was signed by an attorney-in-fact on 08/26/2025.